Literature DB >> 3292283

Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1).

C Miyaura1, K Onozaki, Y Akiyama, T Taniyama, T Hirano, T Kishimoto, T Suda.   

Abstract

Recombinant human interleukin 6 (IL-6), a lymphokine involved in the final differentiation of activated B-cells into antibody-forming cells, greatly suppressed proliferation and induced differentiation of murine myeloid leukemia cells (M1) into mature macrophage-like cells. When M1 cells were treated with IL-6, their growth was completely arrested as early as on day 2, and they were induced to differentiate morphologically into macrophage-like cells. Differentiation-associated properties such as phagocytic activity, adherence to the dish surface, Fc and C3 receptors, were also induced within 24 h by IL-6, and they reached their respective maximal levels on day 2 or 3. The potency of IL-6 in suppressing proliferation and inducing differentiation was much greater than that of 1 alpha,25-dihydroxyvitamin D3 one of the most potent inducers of M1 cells. The present report indicates that IL-6 is involved in the differentiation of not only B-cells but also myeloid leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292283     DOI: 10.1016/0014-5793(88)81293-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

1.  Interleukin-6 is antiproliferative to a mouse hybridoma cell line and promotive for its antibody productivity.

Authors:  F Makishima; S Terada; T Mikami; E Suzuki
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

2.  Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.

Authors:  T Taga; M Narazaki; K Yasukawa; T Saito; D Miki; M Hamaguchi; S Davis; M Shoyab; G D Yancopoulos; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 3.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

4.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130.

Authors:  M Narazaki; B A Witthuhn; K Yoshida; O Silvennoinen; K Yasukawa; J N Ihle; T Kishimoto; T Taga
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 6.  Host defense against infections and inflammations: role of the multifunctional IL-6/IFN-beta 2 cytokine.

Authors:  M Revel
Journal:  Experientia       Date:  1989-06-15

7.  Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells.

Authors:  J Green; S Schotland; Z Sella; C R Kleeman
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo.

Authors:  G J Dougherty; J D Thacker; R S Lavey; A Belldegrun; W H McBride
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

Review 9.  IL-6 cytokine family and signal transduction: a model of the cytokine system.

Authors:  M Hibi; K Nakajima; T Hirano
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

10.  Roles of IL-6-gp130 Signaling in Vascular Inflammation.

Authors:  Tieying Hou; Brian C Tieu; Sutapa Ray; Adrian Recinos Iii; Ruwen Cui; Ronald G Tilton; Allan R Brasier
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.